Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Accretive Health
So what: Revenue improved 30% this quarter, to $163.7 million, but fell just short of analyst estimates, which is weighing on shares. Profit was in line with expectations at $160,000, or $0.04 per share.
Now what: The earnings miss wasn't dramatic and the company reaffirmed full-year guidance in the range of $0.42 to $0.45. That's on the low end of estimates, but the 10% drop the stock is currently experiencing seems excessive. That said, I'm still not jumping into shares because the top end of guidance puts the stock at a hefty 58 P/E multiple for 2011 earnings.
Interested in more info on Accretive Health? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.